Loading
Loading
Research Overview
Binds androgen receptors to upregulate nitrogen retention, muscle protein synthesis, and satellite cell activation. Non-aromatising DHT derivative — does not convert to oestrogen. Reduces SHBG, increasing free androgen fraction. Directly stimulates osteoblast activity contributing to bone density effects.
Overview
Oxandrolone (trade name Anavar) is a dihydrotestosterone-derived anabolic-androgenic steroid first synthesised in the 1960s. Unlike many anabolic steroids, it cannot be converted to oestrogen via aromatisation, and its androgenic potency relative to its anabolic activity is considered low compared to testosterone. These properties have made it a frequently studied compound in both clinical and research contexts.
Decades of published research have examined oxandrolone in populations including burn patients, HIV-associated wasting, Turner syndrome, and paediatric short stature. Preclinical and clinical studies consistently document lean mass preservation and modest increases in nitrogen retention. Hepatic stress, lipid alterations, and axis suppression remain the most frequently characterised adverse findings.
In the research and performance community, oxandrolone is one of the most widely studied oral anabolic agents. Its oral bioavailability, relatively short half-life (~9–10 hours), and moderate suppression profile are frequently cited in comparative AAS pharmacology literature.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, anavar (oxandrolone) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Binds androgen receptors to upregulate nitrogen retention, muscle protein synthesis, and satellite cell activation. Non-aromatising DHT derivative — does not convert to oestrogen. Reduces SHBG, increasing free androgen fraction. Directly stimulates osteoblast activity contributing to bone density effects.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.